Dr Christophe Willekens
- Spécialité
- Hématologue, expert myélome et leucémie
- Hôpital
- Gustave Roussy (Villejuif)
- Derniers articles
-
- Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemia. (1 août 2025)
- Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. (17 avr. 2025)
- Venetoclax-proteasome inhibitor-dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm. (25 févr. 2025)
- Circulating Proteins Associated with Anti-IL6 Receptor Therapeutic Resistance in the Sera of Patients with Severe COVID-19. (1 nov. 2024)
- CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemia. (17 sept. 2024)